The US Food and Drug Administration (FDA) has granted accelerated approval to Astellas Pharma Inc. and Seattle Genetics Inc.'s first-in-class antibody-drug conjugate (ADC) Padcev (enfortumab vedotin-ejfv), providing a new treatment option for later-stage patients with a form of cancer that can currently be very difficult to treat.
Astellas, Seattle Genetics Break Ground With US ADC Approval
Earlier-Stage Combo Also Shows Big Promise
Co-developers gain nod for novel antibody-drug conjugate that provides new option for patients with advanced form of bladder cancer.
More from Anticancer
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.